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Vasomotor symptoms (VMS) experienced during menopause can negatively impact a 
woman’s quality of life, productivity, sleep, and mood. Systemic hormone therapy (HT) is the 
most effective treatment for moderate to severe VMS, however safety concerns raised by the 
2002 Women’s Health Initiative (WHI) trial have led to a decrease in overall HT use and a 
growing demand for custom-compounded bioidentical HT. Misconceptions regarding the 
superior safety and efficacy of custom-compounded hormones and lack of clinician expertise in 
menopause management contribute to ongoing uncertainty and low uptake of United States 
(U.S.) Food and Drug Administration (FDA) approved bioidentical HT products. This literature 
review evaluates current evidence regarding the safety and efficacy of bioidentical HT to provide 
clinical guidance for patient education and prescribing practices. Twenty-eight articles published 
from 2015-2020 were included in the final review, consisting of systematic reviews, meta-
analyses, randomized control trials (RCTs), cohort studies, case control studies, and literature 
reviews. Current evidence suggests that FDA approved bioidentical hormones are more effective 
than placebo and equally effective compared to synthetic hormones when used to treat 
menopausal VMS. Safety of bioidentical HT was evaluated based on its associated risk of breast 
cancer, endometrial cancer, venous thromboembolism (VTE), stroke, and cardiovascular disease 
(CVD). Findings suggest that safety profiles depend on the duration of therapy, route, regimen, 
and individual factors but bioidentical HT is generally safe for women without contraindications 
if low to medium doses are used for five years or less. 
Keywords: menopause, vasomotor symptoms, hot flashes, night sweats, efficacy, 
bioidentical hormone therapy, estradiol, progesterone, safety, breast cancer, endometrial cancer, 
stroke, venous thromboembolism, cardiovascular disease      
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Safety and Efficacy of Bioidentical Hormone Therapy in Menopause: A Literature Review 
Menopause is the cessation of menstruation due to the natural decline in ovarian function 
or surgical removal of the ovaries and can be clinically diagnosed 12 months following the final 
menstrual period (FMP) (Stuenkel et al., 2015). Menopausal VMS including hot flashes and 
night sweats “are associated with a sudden sensation of heat in the face, neck, and chest and 
persist for several minutes or less. Vasomotor symptoms may include flushing, chills, anxiety, 
sleep disruption, and palpitations” (Kauntiz & Manson, 2015, p. 2). The pathophysiology of 
VMS is not completely understood; however, it likely involves altered thermoregulation and 
release of neuroendocrine, cytokine, and stress hormones due to fluctuating sex hormone levels 
(Kaunitz & Manson, 2015).  
The average age of natural menopause in the U.S. is 51 and menopausal transition, or 
perimenopause, may begin as early as age 40 (Kaunitz & Manson, 2015). VMS increase 
throughout perimenopause and peak approximately 1 year after the FMP (Kaunitz & Manson, 
2015). Up to 80% of women experience VMS during the menopausal transition (Gold et al., 
2006; Woods & Mitchell, 2005) and at least 50% report moderate to severe symptoms that 
interfere with quality of life (Freeman et al., 2014). A U.S. observational study showed that 
“frequent VMS lasted more than 7 years during the menopausal transition for more than half of 
the women and persisted for 4.5 years after the FMP” (Avis et al., 2015, p. 531). Frequent and 
severe VMS also occur following oophorectomy due to the sudden shift in estrogen and 
progesterone levels (Kaunitz & Manson, 2015).   
VMS can negatively impact a woman’s occupational, physical, emotional, and sexual 
quality of life and often prompt women in the U.S. to seek medical treatment (Nicholson et al., 
2001; Utian, 2005; Williams et al., 2007). “Untreated menopausal symptoms are also associated 
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with higher health care costs and loss of work productivity” (Manson & Kaunitz, 2016, p. 803). 
Mild VMS can often be managed with lifestyle modifications such as weight reduction, smoking 
cessation, wearing layered clothing, and maintaining a cool environment (Goodman et al., 2011). 
Pharmaceutical treatment options for moderate to severe VMS include systemic HT, selective 
serotonin reuptake inhibitors (SSRIs), serotonin-norepinephrine reuptake inhibitors (SNRIs), 
gabapentin, pregabalin, or clonidine patches (Goodman et al., 2011; North American Menopause 
Society, 2012; Stuenkel et al., 2015). For those without contraindications, estrogen therapy (ET) 
“with or without a progestogen is the most effective treatment of menopause-related vasomotor 
symptoms and their potential consequences, such as diminished sleep quality, irritability, 
difficulty concentrating, and subsequently reduced quality of life (QOL)” (North American 
Menopause Society, 2012, p. 3).  
The dose, route, and regimen of HT can be individualized based on patient preferences, 
risk factors, hysterectomy status, symptomology, and goals of treatment. While systemic 
estrogen only therapy can be prescribed for women who have undergone hysterectomy, a 
progestogen must be added to provide endometrial protection for those with an intact uterus 
(Goodman et al., 2011; North American Menopause Society, 2012; Stuenkel et al., 2015). 
Estrogen is available in oral, transdermal (TD), or vaginal formulations and concurrent 
progestogens may be given orally or vaginally in a combined continuous (CC), sequential 
continuous (SC), or alternate day regimen. With CC estrogen progestogen therapy (EPT), both 
hormones are taken daily and with SC EPT the progestogen is given for 12-14 days each month 
(Yang et al., 2017). The lowest effective dose of HT should be given to control VMS and 
minimize adverse effects such breast tenderness, vaginal bleeding, bloating, and headaches. 
Current guidelines suggest that HT is safe for women “within 10 years of menopause who are at 
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low risk of cardiovascular disease and breast cancer” (Ward & Deneris, 2018, p. 169). Extended 
use may be warranted in some situations after informed, shared decision making, and 
discontinuation of HT should not be based on age alone (Santoro et al., 2019; Ward & Deneris, 
2018).  
The use of systemic HT dramatically decreased among U.S. women after the initial 
findings of the Women’s Health Initiative (WHI) were published in 2002 (Manson & Kaunitz, 
2016). Although the WHI was designed to evaluate the risks and benefits of long-term synthetic 
hormone therapy for postmenopausal women (average age 63 at therapy initiation), it is now 
being used to guide treatment decisions for women in their 40s and 50s who have distressing 
VMS (Manson & Kaunitz, 2016). While there are several FDA approved bioidentical HT options 
and sufficient research to support their use, they remain underutilized in the U.S. (Manson & 
Kaunitz, 2016). This is in part due to the misconception that compounded hormones are safer 
and more ‘natural’ than pharmaceutical bioidentical HT. The purpose of this literature review is 
to synthesize the current evidence regarding the following clinical question: In perimenopausal 
and postmenopausal women, what is the safety and efficacy of bioidentical hormone therapy in 
treating vasomotor symptoms? 
Background 
Initial findings from the WHI trial (Rossouw et al., 2002) reported that the combination 
of conjugated equine estrogen (CEE) with medroxyprogesterone (MPA) (both synthetic 
hormones) increased the risk of coronary heart disease (CHD), stroke, breast cancer, and VTE in 
postmenopausal women. This resulted in a 32% reduction in HT prescriptions and a greater than 
60% reduction in CEE/MPA prescriptions in the U.S. despite further analysis suggesting that the 
WHI findings may not apply to peri- and newly menopausal women (Majumdar et al., 2004). 
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Since that time many women have opted for custom-compounded bioidentical HT “on the 
assumption that it would be safer than other forms of HT” (Gaudard et al., 2016, p. 3).  
Bioidentical hormones from compounding pharmacies are often referred to as ‘natural 
hormones’ and have been marketed as having “fewer risks and side effects, and greater efficacy 
than commercially available HT preparations” (Stanczyk et al., 2021, p. 38). One million to 2.5 
million U.S. women ages 40 and older currently use compounded HT, accounting for 28% to 
68% of HT prescriptions (Pinkerton & Santoro, 2015). Most women who use compounded 
bioidentical HT report that it was recommended by their physician and are not aware that these 
products lack FDA-approval (Pinkerton & Santoro, 2015). Professional organizations including 
the American College of Obstetricians and Gynecologists, American Society for Reproductive 
Medicine, North American Menopause Society, Endocrine Society, American Association of 
Clinical Endocrinologists, and American College of Endocrinology recommend against the use 
of compounded HT “due to concerns regarding reliability of dosage, purity, lack of evidence 
regarding superior effectiveness over FDA-approved hormonal formulations and lack of FDA 
oversight” (Santoro et al., 2019, p. 30). In 2020, the National Academies of Sciences, 
Engineering, and Medicine (NASEM) conducted an extensive study of compounded bioidentical 
HT and recommend prescribers restrict its use to two circumstances: “patients with allergies to 
specific components of FDA-approved hormone therapy, or patients who require a dosage form 
not currently available as an FDA-approved drug product” (p. 195). 
“The term ‘bioidentical hormone’ generally refers to sex steroid hormones, usually an 
estrogen, an androgen or progesterone, that has the same chemical and molecular structure [and 
physiological effect] as the endogenous hormone produced in the body” (Stanczyk et al., 2021, p. 
38). Bioidentical hormones are often derived from natural plant substances; however, all 
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bioidentical hormones, whether they are custom-compounded or pharmaceutical formulations, 
require some degree of chemical synthesis in the lab (Stanczyk et al., 2021). Synthetic hormone 
is a term used to describe formulations that differ in chemical structure and physiologic effect 
compared to endogenous hormones (Stanczyk et al., 2021). It is implied that all synthetic 
hormones are ‘manufactured’ in the lab, which is not the case. Conjugated equine estrogen 
(CEE) is derived from female horse urine and does not require any chemical synthesis, however 
it is considered a synthetic estrogen because it does not share the same chemical and physiologic 
properties as human estrogen (Stanczyk et al., 2021). 
The following terms will be used in this literature review to differentiate between 
bioidentical and synthetic formulations. Progestogen encompasses both synthetic progestin (P) 
and bioidentical progesterone (P4). Bioidentical estrogen encompasses estrone (E1), estradiol 
(E2), estriol (E3), and estetrol (E4). E2 and E3 are widely used in Europe and Asia but only E2 
products are FDA approved for use in the U.S. (Moskowitz, 2006). Custom compounded HT 
formulations may include any combination of P4, E1, E2, or E3 (Stanczyk et al., 2021). 
FDA approved 17-beta estradiol is available in the U.S. in oral, transdermal, and vaginal 
formulations; under generic and brand names such as Estrace, Alora patch, and Vagifem 
(Santoro et al., 2019). Products combining oral or transdermal 17-beta estradiol with a synthetic 
progestin are also available (i.e. Activella, Climara Pro) (Santoro et al., 2019). Not all estradiol 
products are bioidentical which can create confusion for patients and clinicians; for example 
estradiol acetate is considered bioidentical whereas ethinyl estradiol is synthetic. Bioidentical P4 
is available in an oral micronized formulation prepared in peanut oil (Prometrium), vaginal 
preparation (Prochieve 4%), or in a combined oral capsule with 17-beta estradiol (Bijuva) 
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(Santoro et al., 2019). MPA, norethindrone acetate (NETA), and levonorgestrel (LNG), are 
synthetic progestins that are completely man-made (Stanczyk et al., 2021).  
Numerous FDA approved formulations of 17-beta estradiol and progesterone are 
available for U.S. women seeking bioidentical HT for the treatment of menopausal VMS. 
Clinicians caring for menopausal women often report having received inadequate training and 
many do not realize that FDA approved bioidentical hormones are available (Kling et al., 2019; 
Files et al., 2016; Manson & Kaunitz, 2016). This leads to reluctance in prescribing HT and 
ineffective counseling of women who might benefit from bioidentical therapies.  
Method 
Data abstraction process  
A literature search was completed from 10/24/20 to 1/17/21 using CINAHL, Academic 
Search Premier, PubMed, and Cochrane Database of Systematic Reviews. Table 1 in the attached 
appendix includes details on search restrictions, dates included, and general subjects covered by 
each database.  
Study Selection  
Search terms comprised of “bioidentical hormone replacement therapy”, “bioidentical 
hormones", “menopause”, “perimenopause”, “vasomotor symptoms”, “estradiol”, “CEE”, 
“conjugated equine estradiol”, “progesterone”, “REPLENISH trial”, “safety”, “risk”, and 
“cancer”. Search limits included publications from 2015-2020, full text availability, English 
language, and peer reviewed academic journals. Articles were initially reviewed and eliminated 
if the title and abstract did not address the clinical question. Duplications were also eliminated. A 
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bibliographic review identified five additional articles that were ultimately included. See Table 2 
in the appendix for search term combinations and the number of unique hits from each database. 
Search Strategies  
Table 3 in the appendix includes all articles that were reviewed for inclusion or exclusion 
criteria. Articles were included if they (1) included perimenopausal and/or postmenopausal 
women, (2) evaluated the efficacy of oral or TD bioidentical hormones in treating VMS, (3) 
evaluated the safety of bioidentical hormones regarding VTE, stroke, cardiovascular, breast 
cancer, or endometrial cancer risk, (4) compared bioidentical HT to non-users, placebo, and/or 
synthetic HT, or (5) compared various formulations, doses, regimens, or routes of bioidentical 
HT. Articles were excluded if they (1) evaluated the safety or efficacy of low-dose vaginal 
estrogen, (2) measured menopausal outcomes of genitourinary symptoms, sleep quality, or 
mood, (3) were expert reviews or commentary on original studies, (4) were available in abstract 
only, (5) or did not differentiate between bioidentical and synthetic hormones when evaluating 
the efficacy or risk of HT.   
Literature Review Process  
Twenty-eight articles met inclusion criteria and consisted of systematic reviews, meta-
analyses, RCTs, case control studies, cohort studies, and literature reviews. The systematic 
reviews and meta-analyses included large, well-designed RCTs, observational, and population-
based case control and cohort studies. Retrospective observational studies often relied on 
insurance claims to determine HT use, type of HT, co-morbid conditions, and participant 
demographics. This introduced a potential for error in International Classification of Diseases, 
Tenth Revision (ICD-10) coding, and did not provide specific dosing, duration, regimen, or 
10 
 
adherence data. Safety studies were more likely to be observational in nature compared to 
efficacy studies due to the longer duration required to evaluate for risk and the associated cost of 
long-term controlled studies.  
Methodological Assessment  
The twenty-eight articles included in the literature review were categorized into three 
groups: bioidentical HT efficacy, safety, or both. The safety articles were further categorized into 
five groups: breast cancer, endometrial cancer, VTE, stroke, or cardiovascular disease. 
Synthesizing the data was challenging due to heterogeneity of the studies and numerous factors 
impacting safety outcomes. The search terms and databases most likely to yield results were 
utilized for this literature review, however it is possible that some relevant literature was missed. 
By limiting search dates to the past five years, older studies with valuable findings may have 
been excluded, but the systematic reviews and meta-analyses included in this review encompass 
individual studies dating back over 20 years. This literature review therefore represents the 
current state of evidence regarding the safety and efficacy of bioidentical HT for the treatment of 
menopausal VMS.   
Literature Review 
Efficacy of Oral Estradiol  
Gaudard et al. (2016) conducted a systematic review and meta-analysis of 23 RCTs 
comparing the efficacy of 17-beta estradiol to CEE or placebo and found low to moderate quality 
evidence suggesting that bioidentical estradiol is more effective than placebo in treating 
moderate to severe VMS. Efficacy was dose dependent but higher doses also resulted in more 
adverse effects such headache, vaginal bleeding, breast tenderness, and skin reactions. There was 
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no evidence to suggest a difference in efficacy between estradiol and CEE. The authors were 
unable to make specific treatment recommendations due to individual study limitations including 
risk of bias due to poor reporting of methods, imprecision, and lack of analyzable data.  
The REPLENISH trial (Lobo et al., 2018) investigated the efficacy of TX-001HR, a 
combined oral E2/P4 capsule, given daily at various doses to treat moderate to severe VMS. 
Frequency and severity of VMS significantly decreased from baseline with the 1mg/100mg and 
0.5mg/100mg doses compared to placebo at week 4 and week 12. Additional analyses of the 
REPLENISH trial demonstrated a clinically meaningful reduction in hot flashes (Constantine et 
al., 2019) and more VMS-free days (Kaunitz et al., 2020) in the treatment groups versus placebo.  
Coelingh Bennink et al. (2016) conducted a small, partly randomized open-label, 
multiple-rising-dose study (N=49) comparing the efficacy of 2mg oral estradiol valerate (E2V) 
and 2mg and 10mg oral E4 in treating postmenopausal VMS. Oral E4 is a weak estrogen steroid 
hormone produced by the fetal liver and is only present at detectable levels during human 
pregnancy (Coelingh Bennink et al., 2016). Neither of these products are FDA approved for 
menopausal HT however oral E2V is widely used in Europe. Participants with an intact uterus 
were randomized to receive 2mg of unopposed E2V or 2mg of unopposed E4 on days 1-28. 
During the dose escalation phase of the study, women who experienced 35 or more hot flashes 
per week at baseline were then given 10mg of E4 on days 29-56. Hot flashes and sweating were 
recorded in a daily diary by all participants on days 1-56. The authors concluded that all 
treatment groups were equally effective at decreasing VMS (see Table 4).   
 Efficacy of Transdermal Estradiol 
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Transdermal estradiol can be administered as a gel, patch, or spray to treat moderate to 
severe VMS in menopause. Derzko et al. (2016) performed a systematic review and network 
meta-analysis to indirectly compare the efficacy of several estradiol gels and doses. The authors 
concluded that Divigel 0.25 mg, Divigel 0.5 mg, and Estrogel 0.75 mg showed similar efficacy 
and were all statistically superior to Estrogel 1.5 mg (see Table 4). Divigel 1.0 mg provided the 
best efficacy profile but was also associated with a higher risk of adverse effects including 
postmenopausal bleeding, headache, breast pain, infection, nausea, rash, and vaginitis. The 
discontinuation rate with Divigel 1.0 mg was only 5% which suggests that the benefits of 
improved efficacy may outweigh the risk of adverse effects for some women.   
A systematic review and network meta-analysis by Kovács et al. (2016) indirectly 
compared the efficacy of estradiol metered dose transdermal spray (MDTS) and estradiol patches 
given at doses ranging from 14-50mcg. Both formulations resulted in similar reductions in hot 
flash frequency over a 12-week period with a dose dependent response. All but the 14mcg 
estradiol patch resulted in statistically significant improvements in VMS when compared to 
placebo. These findings suggest that estradiol MDTS and estradiol patches produce comparable 
reductions in VMS when given at similar doses. 
Efficacy of Low-Dose Estradiol 
The Kronos Early Estrogen Prevention Study (KEEPS) (Harman et al., 2005) was a 
multicenter RCT that compared the effects of low-dose oral CEE (0.45mg), TD estradiol 
(50mcg), and a placebo on cardiovascular outcomes in recently menopausal women (average 22 
months post FMP). A secondary analysis of the KEEPS trial by Santoro et al. (2017) showed that 
both treatment arms experienced a significant and similar reduction in moderate to severe VMS 
when compared to the placebo group. Subgroup analyses also showed that symptom relief was 
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not significantly modified by body mass index (BMI), race, or ethnicity (Santoro et al., 2017). 
The authors concluded that “recently menopausal women had similar and substantial reductions 
in hot flashes and night sweats with lower than conventional doses of oral or TD estrogen. These 
reductions were sustained over 4 years” (Santoro et al., 2017, p. 3).   
Malik et al. (2016) conducted a randomized single blind, four arm, parallel assignment 
study (N=200) comparing the efficacy of low-dose oral E2V, oral CEE, and a placebo in 
reducing postmenopausal VMS. Self-reported severity and frequency of hot flashes were used to 
calculate a hot flash score (average hot flash severity x daily frequency). Follow up at 24 weeks 
revealed a significant reduction in mean hot flash score for both E2V and CEE (91.9% and 
89.2% reduction respectively). The authors concluded that low doses of oral E2V and CEE were 
equally effective in treating VMS over 24 weeks.   
A systematic review of nine double blind placebo-controlled trials (N=3069) by Corbelli 
et al. (2015) found that low-dose TD estradiol (less than 50mcg) was more effective than placebo 
at reducing the frequency of moderate to severe hot flashes. A dose dependent response was 
observed with estradiol doses ranging from 0.003mg-0.045mg (see Table 4).   
Efficacy of Progesterone Only Therapy  
Progesterone only therapy can be used to treat VMS in women who have 
contraindications or a personal preference to avoid estrogen. Systematic reviews by Dolitsky et 
al. (2021) and Prior (2018) included a limited number of smaller RCTs that showed mixed 
therapeutic efficacy of standalone progesterone. One RCT (N=133) concluded that 300mg of 
daily oral micronized P4 significantly decreased VMS scores in the treatment group compared to 
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placebo (Hitchcock & Prior, 2012). There is insufficient evidence to support the use of low-dose 
TD P4 for menopausal VMS (Prior, 2018).   
Safety of Bioidentical HT: Breast Cancer 
The E3N-Epic study by Fournier et al. (2005) was a prospective study (N=98,997) 
conducted in France that followed menopausal women over an eight-year period and calculated 
the hazard ratio (HR), or likelihood of developing breast cancer after receiving HT. A hazard 
ratio of 1.0 indicates that the HT intervention had no impact on the outcome (breast cancer) 
whereas HR greater than 1.0 represents an increased risk and HR less than 1.0 represents a 
decreased risk (Melnyk & Fineout-Overholt, 2015). Fournier et al. (2005) concluded that breast 
cancer risk was lowest for those receiving bioidentical EPT (HR 0.9; 95% CI 0.7, 1.2) and 
bioidentical ET (HR 1.1; 95% CI 0.8, 1.6), and higher for those receiving bioidentical estrogen 
with synthetic progestin (HR 1.4; 95% CI 1.2, 1.7). These findings suggest than regimens 
containing a synthetic progestin pose a greater risk of breast cancer than bioidentical 
formulations.  
A retrospective study by Zeng et al. (2018) compared breast cancer incidence among 
12,404 women who received various types of HT after age 50 and 27,642 non-HT users. The 
authors concluded that ET with CEE or estradiol both resulted in a significant reduction in breast 
cancer risk (see Table 4). CEE plus MPA also significantly reduced breast cancer risk which 
conflicts with previous WHI findings (Rossouw et al., 2002). A non-significant increase in breast 
cancer risk occurred with estradiol plus progesterone (see Table 4). In a direct comparison of the 
two combination therapies, the authors concluded that CEE plus MPA is superior to estradiol 
plus progesterone from a breast cancer safety standpoint.  
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A systematic review and meta-analysis by Yang et al. (2017) evaluated breast cancer risk 
associated with unopposed estradiol and estradiol plus progestogen including subgroup analysis 
based on progestogen type, duration of exposure, and regimen. All 14 studies used E2V or 17-
beta estradiol with a synthetic progestin or micronized P4, however doses and routes of 
administration were not specified. Breast cancer risk was increased in the EPT group, but 
subgroup analysis showed that the risk varied based on progestogen type. A statistically 
significant increase in breast cancer risk was noted with EPT containing synthetic progestins 
(MPA, NETA, and LNG) but there was no increased risk with EPT containing oral micronized 
P4 or dydrogesterone (see Table 4). Estradiol-only therapy showed no increased risk of breast 
cancer (see Table 4). Bioidentical estradiol combined with a progestogen increased breast cancer 
risk when used for longer than five years; however, the authors were unable to perform subgroup 
analysis based on progestogen type due to small sample sizes. Bioidentical estradiol given with 
CC or SC progestogen increased breast cancer risk with more significant risk associated with a 
CC regimen.  
Stute et al. (2018) conducted a systematic review evaluating breast cancer incidence 
associated with EPT containing micronized P4. Estrogen (synthetic or bioidentical) paired with 
oral or vaginal P4 did not increase breast cancer risk if used for five years or less. However, 
limited evidence suggests that breast cancer risk increases after five years. Only two studies 
(Espié et al., 2007; Fournier et al., 2005) measured breast cancer incidence after five years of HT 
use; both were prospective cohort studies and lacked detailed reporting of compliance, dosage, 
and route of P4.   
A systematic review of three observational studies (N=86,881) compared breast cancer 
risk based on progestogen type (Asi et al., 2016). Meta-analysis conducted on two of the cohort 
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studies showed that EPT with P4 may be associated with lower breast cancer risk compared to 
EPT with synthetic progestin (RR 0.67; 95% CI 0.55-0.81) however the included studies had a 
moderate risk of bias (Asi et al., 2016). A population-based case control study showed no 
increased risk of breast cancer associated with estrogen plus progesterone, (OR 0.80; 95% CI 
0.44–1.43) and a non-significant increase with estrogen plus progestin, (OR 1.57; 95% CI 0.99-
2.49) (Cordina-Duverger et al., 2013). Findings suggest that P4 may be safer than progestins, 
however study limitations include the risk of bias and confidence intervals crossing the null 
hypothesis (1).  
Safety of Bioidentical HT: Endometrial Cancer 
Mirkin et al. (2020) conducted a secondary analysis of the REPLENISH trial (Lobo et al., 
2018) and concluded that all doses of the combined E2/P4 capsule provided adequate 
endometrial protection for up to one year. Coelingh Bennink et al. (2016) measured endometrial 
thickness over an eight-week period of daily unopposed E4 use. The 10mg dose resulted in 
endometrial hyperplasia but the 2mg dose did not. Findings suggest that higher doses of E4 
require endometrial protection with a progestogen whereas the 2mg dose may not. 
Systematic reviews by Sjögren et al. (2016) and Tempfer et al. (2020) evaluated 
endometrial cancer risk based on type of progestogen and regimen used. Both reviews included 
two large European cohort studies (Allen et al., 2010; Fournier et al., 2014) and concluded that 
micronized P4 increases endometrial cancer risk (see Table 4). Subgroup analysis of the E3N 
study (Fournier et al., 2014) found that short term use (five years or less) of P4 may be safe; 
however, endometrial cancer risk increased after five years of use. A large systematic review by 
Stute et al. (2016) included 40 studies utilizing EPT with various forms, regimens, and doses of 
P4 and concluded:  
17 
 
(1) oral micronized progesterone provides endometrial protection if applied sequentially 
for 12–14 days/month at 200 mg/day for up to 5 years; (2) vaginal micronized 
progesterone may provide endometrial protection if applied sequentially for 10 
days/month at 4% (45 mg/day) or every other day at 100 mg/day for up to 3–5 years (off-
label use); (3) transdermal micronized progesterone does not provide endometrial 
protection. (p. 327) 
Safety of Bioidentical HT: Cardiovascular Disease, VTE, and Stroke 
Simon et al. (2016) were the first to provide a direct comparison of oral estrogen and TD 
estradiol. In this large matched cohort study (N=5102) conducted over a 10-year period, women 
receiving TD estradiol were found to have a significantly lower incidence of CVD events 
compared with those receiving oral ET (see Table 4). Subgroup analysis revealed statistically 
significant reductions of VTE overall, DVT, and heart failure; and non-statistically significant 
reductions of pulmonary embolism, myocardial infarction, stroke, transient ischemic attack, and 
angina in the TD estradiol group compared to the oral ET group. Unfortunately, the type of oral 
estrogen was not specified in this study, so it is unclear if patients received synthetic or 
bioidentical formulations.   
A nested case control study in France (Canonico et al., 2016) identified 3,144 women 
who were hospitalized for their first episode of ischemic stroke (IS) and 12,158 matched 
controls. Insurance claims data were obtained to identify current users of oral or TD 17-beta 
estradiol (with or without a progestogen) and odds ratios were adjusted based on medications and 
diagnostic codes for diabetes, hypertension, and dyslipidemia. Compared to nonusers, oral E2 
was found to increase IS risk in a dose dependent manner whereas no increased risk occurred 
with TD E2 (see Table 4). The authors also investigated IS risk based on progestogen type and 
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found that TD E2 plus P4 did not increase IS risk whereas TD E2 plus synthetic norpregnane 
derivatives did (see Table 4).  
A meta-analysis of seven well-designed population-based observation studies evaluated 
VTE risk based on progestogen type and found that “in transdermal estrogen users, there was no 
change in VTE risk in women using micronized progesterone (RR 0.93, 95% CI 0.65–1.33), 
whereas norpregnane derivatives were associated with increased VTE risk (RR 2.42, 95% CI 
1.84–3.18)” (Scarabin, 2018, p. 341).  
Lobo et al. (2019) completed a secondary analysis of the REPLENISH trial (Lobo et al., 
2018) and found that continuous oral E2/P4 had no significant effect on cardioembolic markers 
including lipids, coagulation factors, or blood glucose. The non-significant effect on triglyceride 
levels seen with the E2/P4 capsule were similar to findings by Harman et al. (2005) using TD E2 
and cyclic P4. Although the study by Lobo et al. (2019) lacked statistical power to determine 
cardiovascular outcomes such as stroke, VTE, and coronary heart disease, the incidence of 
cardiovascular events in those receiving the E2/P4 capsule was comparable to expected rates in 
the general population. 
A single center RCT by Hodis et al. (2016) explored the relationship between timing of 
HT initiation and progression of subclinical atherosclerosis, measured by carotid-artery intima-
media thickness (CIMT). Healthy post-menopausal women (N=643) were randomized to receive 
oral 17-beta estradiol (with SC vaginal progesterone if their uterus was intact) or a placebo. For 
women in early menopause (less than 6 years since FMP), the rate of CIMT progression was 
significantly lower in the estradiol group than in the placebo group. Women in late menopause 
(10 years or more since FMP) did not demonstrate any difference in CIMT progression as 
compared to the control group (see Table 4). Estradiol had no significant impact on clinical 
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atherosclerosis in either group; however, cardiac computed tomography was not performed at 
baseline and not all participants followed up after study completion. 
Limited evidence suggests that P4 does not diminish the cardiovascular benefits of 
estrogen and is likely safer than progestins; however, existing RCTs have not measured coronary 
heart disease directly (Eden, 2017). Asi et al. (2016) attempted to conduct a systematic review 
and meta-analysis of studies comparing cardiovascular events with EPT containing P4 versus 
progestin. The authors were unable to find any studies that met inclusion criteria and suggested 
that further research be conducted in this area. When given at 300mg daily for 12 weeks to treat 
VMS, oral P4 caused no change in weight, waist circumference, blood pressure, fasting glucose, 
lipids, C-reactive protein, or D-dimer compared to placebo (Prior, 2018).   
Quality Indicators 
This literature review included systematic reviews, meta-analyses, RCTs, and prospective 
and retrospective observational studies with varied sample sizes, risk of bias, reporting detail, 
and heterogeneity which made it difficult to interpret findings and formulate specific 
recommendations for clinical practice. Most of the efficacy studies were RCTs whereas safety 
studies were more often observational in nature. The observational studies allowed for longer 
duration of follow up and larger sample sizes but were limited by the lack of control groups. 
Multiple studies also provided limited details regarding HT doses, routes, and formulations. 
Many studies were well-designed with adequate sample sizes to power statistical significance, 
yet the confidence interval occasionally crossed 1 (e.g. 95% CI 0.9-1.1) which implies no 
difference between arms of the study (Melnyk & Fineout-Overholt, 2015). Many studies reported 
a low risk of bias or explained methods used to exclude studies with higher bias.  
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Variables such as hormone formulation, dose, regimen, route, application method, 
participant age, timing of HT initiation, severity of symptoms, and health status impact the 
outcomes of interest and complicate the evaluation and synthesis of research findings. This 
review included studies conducted in the U.S. and Europe, therefore some of the HT 
formulations are not FDA approved or available in the U.S. Dropout rates were reported in some 
studies and although significant at times, re-analysis often confirmed that results were not 
impacted by attrition. Studies reported severity and/or frequency of VMS using a validated tool 
or self-report method. Validated tools increase the accuracy of VMS reporting but also increase 
the burden on participants and may lead to higher attrition rates. VMS diaries were maintained 
before and during the treatment period which promoted accurate recall of symptoms. The 
REPLENISH trial was funded and supported by TherapeuticsMD, manufacturer of the now FDA 
approved Bijuva, however bias was minimized due to its double blinded, randomized design. 
Gaps in Literature  
            Overall there was a lack of diversity in study subjects with most participants being white, 
non-Hispanic, healthy, and well educated. Additional research is needed to evaluate the safety 
and efficacy of bioidentical HT in a more ethnically and socially diverse population and in 
women with underlying health conditions. There is also a needed for well-designed RCTs 
comparing different doses, regimens, and routes of bioidentical hormones. It is difficult to 
determine long-term safety outcomes with RCTs due to their relatively shorter duration 
compared to observational studies, however observational studies lack controls and are more 
prone to bias. Research regarding the safety of low-dose TD estradiol is lacking particularly in 
the areas of cardiovascular disease and breast cancer risk. Additional research involving 





Evidence suggests that various doses of TD and oral estradiol, including lower than 
standard TD doses, are more effective than placebo in reducing menopausal VMS (Gaudard et 
al., 2016; Kovács et al., 2016; Lobo et al., 2018; Santoro et al., 2017) and equally effective 
compared to synthetic estrogen/CEE (Corbelli et al., 2015; Malik et al., 2016; Santoro et al., 
2017). The efficacy of low-dose TD E2 (50mcg/day) was consistent across ethnic and racial 
groups and was not impacted by BMI (Santoro et al., 2017). TD and oral estradiol reduce VMS 
in a dose dependent manner however higher doses often result in unwanted adverse effects, 
which may lead to discontinuation (Corbelli et al., 2015; Derzko et al., 2016; Gaudard et al., 
2016). When given in equivalent doses, estradiol TD patches and MDTS were equally effective 
although MDTS may produce fewer localized skin reactions resulting in better tolerability and 
adherence (Kovács et al., 2016).  
The E2/P4 combined daily capsule studied in the REPLENISH trial resulted in 
statistically significant (Lobo et al., 2018) and clinically meaningful (Constantine et al., 2019) 
reductions in the frequency and severity of VMS and more symptom free days (Kaunitz et al., 
2020) compared to a placebo. The 1mg/100mg dose has since been approved by the FDA, under 
the brand name Bijuva, as the first combined bioidentical EPT for the treatment of menopausal 
VMS. Once daily dosing with a single combined capsule may improve patient adherence and 
control of symptoms. Unlike oral micronized progesterone, Bijuva does not contain peanut oil 
and can be safely used by those with a peanut allergy.  
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E4 may be a safe and effective bioidentical HT option for treating menopausal VMS 
(Coelingh Bennink et al., 2016) but is not currently approved for use in the U.S. or Europe. 
Additional E4 research is needed with larger sample sizes and longer duration of treatment. 
Evidence is lacking to support widespread use of progesterone-only therapy to treat VMS; 
however, it may be an option for women who are unable or unwilling to use systemic estrogen. 
Barriers to using progesterone-only treatment include lack of provider awareness and patient 
discontinuation due to headache and vaginal bleeding (Dolitsky et al., 2021; Prior, 2018).   
Breast Cancer 
Research suggests that EPT containing P4 does not increase breast cancer risk and is 
safer than EPT with synthetic progestins (Asi et al., 2016; Fournier et al., 2005; Yang et al., 
2017; Zeng et al., 2018). Estradiol plus P4 resulted in a non-significant increase (Zeng et al., 
2018) or no change in breast cancer risk (Fournier et al., 2005), and estradiol plus synthetic 
progestin increased breast cancer risk (Yang et al., 2017). ET (estradiol or CEE) was found to 
decrease or have no significant effect on breast cancer risk (Fournier et al., 2005; Zeng et al., 
2018). EPT with synthetic or bioidentical estrogen plus oral or vaginal P4 did not increase breast 
cancer risk if used for five years or less; limited evidence suggests that this risk may increase 
after five years (Stute et al., 2018). No conclusions can be drawn regarding breast cancer risk 
associated with SC and CC regimens containing P4 due to inadequate sample sizes (Stute et al., 
2018). Most studies evaluating breast cancer risk did not specify HT doses, routes, or regimens 
however current evidence suggests that ET (synthetic or bioidentical) and EPT with oral or 




Women with an intact uterus should receive EPT due to the increased risk of endometrial 
cancer associated with unopposed estrogen (Goodman et al., 2011). Oral P4 provides adequate 
endometrial protection when given continuously at 100mg (Eden, 2017; Lobo et al., 2018) or 
sequentially at 200mg (Eden, 2017; Stute et al., 2016). Vaginal P4 can be administered every 
other day at 100mg or sequentially at 4% (45 mg/day) for 10 days per month (Eden, 2017; Stute 
et al., 2016). Transdermal P4 does not provide adequate endometrial protection (Stute et al., 
2016). Short term use (five years or less) of oral P4 for endometrial protection did not 
statistically increase the incidence of endometrial cancer (Sjögren et al., 2016; Tempfer et al., 
2020). Continuous oral P4 may provide greater endometrial protection than cyclic use however 
neither regimen resulted in elevated endometrial cancer risk after five years (Tempfer et al., 
2020). Since there is no clinical benefit to giving oral P4 sequentially, continuous use is 
recommended to minimize endometrial cancer risk (Zeng et al., 2018).  
Cardiovascular, VTE, and Stroke 
Oral E2 was found to increase VTE and IS risk in a dose dependent manner however no 
increased risk occurred with TD E2 or TD E2 plus P4 (Canonico et al., 2016; Scarabin et al., 
2018; Simon et al., 2016). These findings suggest that “TD estrogens alone or combined with 
micronized progesterone may be the best option to improve the risk benefit ratio of HT use and 
may represent the safest option with respect to both VTE and stroke risk” (Canonico et al, 2016, 
p. 1740). 
Research on bioidentical HT and CVD is lacking. None of the included studies measured 
CVD directly and instead used surrogate markers such as lipids, vascular function, weight, waist 
circumference, blood pressure, and fasting glucose. While these markers represent CVD risk 
factors, they do not always predict future development of CVD. Findings from the REPLENISH 
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trial showed no significant effect on cardioembolic markers with all doses of the E2/P4 capsule 
(Lobo et al., 2019). Standalone P4 used to treat VMS may also have a neutral effect on surrogate 
markers for CVD (Prior, 2018). One RCT (Hodis et al., 2016) found that estradiol may slow the 
progression of subclinical atherosclerosis if initiated within six years of menopause, however the 
authors acknowledged that CIMT is not the only predictor of CVD.  
Implications for Future Practice 
Recommendations for Clinical Practice  
Clinicians have a responsibility to their patients “to ensure that their decision making is 
based on evidence-based health information and is supported by techniques of shared decision 
making” (NASEM, 2020, p. 196). Based on current evidence, clinicians can confidently 
recommend FDA approved bioidentical hormones to women who are seeking an alternative to 
conventional synthetic hormones, have no contraindications to HT, and experience moderate to 
severe VMS despite lifestyle modifications. If bioidentical HT is prescribed, clinicians should 
initiate oral or TD estradiol at a low-dose (0.003mg-0.05mg) and titrate to optimally balance 
symptom control with adverse effects. The timing of HT discontinuation should be 
individualized and never based on age alone, although discontinuation within five years may 
pose a lower risk of breast and endometrial cancer depending on the regimen. CC, SC, or 
alternate day vaginal P4 provides adequate endometrial protection in women with an intact 
uterus. There are a variety of FDA approved formulations available to meet the needs of most 
women. Custom-compounded hormones should generally be avoided except for rare cases where 
a woman does not tolerate FDA approved therapies due to allergies or the recommended dose is 
not commercially available (NASEM, 2020).  
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Recommendations for Research  
            Additional well-designed RCTs and observational studies evaluating various routes, 
doses, and regimens of FDA approved bioidentical hormones are needed to determine which are 
safest and most effective in treating VMS. These studies should include a broad and diverse 
demographic sample (ethnicity, race, health status, education, etc.), longer duration of follow-up, 
adequate sample sizes, and direct comparison of different bioidentical hormones. Current gaps in 
the literature include direct comparisons of TD E2 preparations, RCTs evaluating the efficacy of 
oral P4 in treating VMS, and safety studies evaluating the impact of bioidentical HT on CVD. 
Additional research involving perimenopausal women is also needed as most studies included 
postmenopausal women only. Well-designed RCTs are needed to better understand the potential 
health benefits and risks, scope, and financial costs associated with commonly prescribed 
compounded bioidentical HT preparations.  
Recommendations for Education  
Physicians and advance practice providers often receive inadequate training in 
menopause management which leads to uncertainty and confusion regarding the efficacy and 
safety of HT, ineffective counseling of women seeking care, and overall reluctance to prescribe 
HT for those who may benefit (Manson & Kaunitz, 2016). Primary care and OB-GYN residency 
programs and advanced practice provider programs should include menopause management as a 
core competency and provide clinical opportunities to further develop knowledge and skills. 
Advanced practice provider fellowship programs are one option for newly graduated family 
nurse practitioners and physician assistants to gain women’s health experience. Ongoing 
continuing education should be offered to primary care and women’s health providers to ensure 
that evidence-based recommendations are being implemented in practice. 
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Recommendations for Policy  
             Collaboration between the FDA, state medical and pharmacy boards, and other 
stakeholders is needed to increase state and federal regulatory oversight of custom compounded 
bioidentical HT to ensure that adequate quality standards are maintained and documented 
(NASEM, 2020). Oversight should also include processes to improve data collection and 
surveillance of adverse events associated with compounded products. Compounding pharmacies 
are not currently required to include comprehensive product labels or standardized package 
inserts which:   
provide opportunities for ambiguous instructions for use, incomplete listing of active and 
inactive ingredients, or an omission of potential contraindications, all of which creates the 
potential for patients and prescribers to be inadequately informed about possible safety 
concerns related to the use of these medications. (NASEM, 2020, p. 6)   
Additional labeling and packaging requirements including black box warnings, non-FDA 
approved status, indications and guidance for use, dosage, ingredients, expiration date, 
contraindications, side effects, and instructions on how to report adverse events would enhance 
patient awareness and safe use of compounded HT (NASEM, 2020).   
Conclusion 
FDA approved bioidentical hormones provide a safe and effective treatment option for 
peri- and postmenopausal women with moderate to severe VMS who are seeking a bioidentical 
option and have no contraindications to HT. Bioidentical HT is available in a variety of 
formulations, doses, routes, and regimens, is more effective than placebo, and equally effective 
compared to synthetic hormones. Research included in this literature review suggests that 
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estradiol and progesterone are generally safe to use from a breast cancer, endometrial cancer, 
VTE, and stroke perspective although safety depends on the route, dose, regimen, duration of 
treatment, and individual risk factors. Estradiol with or without P4 poses no additional risk of 
breast cancer if used for five years or less. TD estradiol with or without P4 is safer than oral 
estrogen or EPT with progestin when considering VTE risk. Oral E2 was found to increase 
ischemic stroke risk in a dose dependent manner however no increased risk occurred with TD E2 
or TD E2 plus P4. Additional research is needed to evaluate CVD risk although research with 
surrogate markers are reassuring. “Midwives and nurse practitioners are ideally suited to provide 
evidence‐based care for menopause‐related symptoms as professionals committed to assessing 
each woman based on her overall risks and personal preferences” (Ward & Deneris, 2018, p. 
168). This includes counseling women on the risks and benefits of FDA approved bioidentical 
HT, recommending its use when clinically appropriate, and offering an individualized treatment 
plan to effectively reduce VMS and improve the quality of life for women during the menopause 
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Maturitas, 91, 93–100. 
https://doi.org/10.1016/j.matu
ritas.2016.06.017 
 Netherlands DV=Endometrial 
thickness: 
ultrasound at 
baseline, day 14, 
28, and 56. 
endometrial 
biopsy at baseline 
and day 28 if 
















2mg: 9  5.6; E4 10mg: 
8.4  5 
Sweating (episodes/day): 
E2V 2mg: 3.5  2.3; E4 
2mg: 4.4  2.4; E4 10mg: 
2.6  1.4 
VMS at day 56 follow up: 
Hot flashes (episodes/day): 
E2V 2mg 1.8; E4 2mg 1.8; 
E4 10mg 1.8 
Sweating (episodes/day): 
E2V 2mg 0; E4 2mg 1.6; 
E4 10mg 0.9  
Endometrial thickness: 
E4 2mg: stable   
E2V 2mg & E4 10mg: ↑  
endometrial protection with 
progestogen is necessary for 
10mg dose but may not be 
needed for 2mg dose. 
 
Further research of E4 in 
treating menopausal VMS is 
needed with a minimum 
treatment time of 12 weeks to 
further evaluate safety and 
efficacy. 
 
Small phase I and II studies 
cannot be generalized to 
practice without further 
research.  
Constantine, G. D., Revicki, 
D. A., Kagan, R., Simon, J. 
A., Graham, S., Bernick, B., 
& Mirkin, S. (2019). 
Evaluation of clinical 
meaningfulness of estrogen 
plus progesterone oral capsule 
(TX-001HR) on moderate to 
severe vasomotor symptoms. 

















DV= CID and 
minimal CID in 
VMS severity at 

















or placebo  
Significantly more women 
had a clinically meaningful 
improvement in the 
number of hot flashes in all 
treatment groups versus 
placebo  
TX-001HR provided clinically 
meaningful improvements in 


























Corbelli, J., Shaikh, N., 
Wessel, C., & Hess, R. 
(2015). Low-dose transdermal 
estradiol for vasomotor 
symptoms: A systematic 






low dose TD 






































All doses of TD E more 
effective than placebo  







0.0125 mg: ↓7.07  
Placebo groups: ↓5.07.  
Strong evidence to suggest 
that low-dose TD E is more 
effective than placebo in 
reducing the frequency of 
moderate to severe hot flashes. 
 
Dose dependent relationship 
observed 
Derzko, C., Sergerie, M., 
Siliman, G., Alberton, M., & 
Thorlund, K. (2016). 
Comparative efficacy and 
safety of estradiol transdermal 
preparations for the treatment 
of vasomotor symptoms in 
postmenopausal women: An 
indirect comparison meta-








for the treatment 




























Divigel 0.25 mg, Divigel 
0.5 mg, and Estrogel 0.75 
showed similar efficacy 
and all were statistically 
superior to Estrogel 1.5 
mg. 
Best efficacy profile 
Divigel 1.0mg (mean 
difference 3.91 hot 
flushes/week vs placebo) 
Best efficacy profile resulted 
from Divigel 1.0mg, but also 
associated with higher risk of 
AEs compared to other 
formulations. Despite AEs, 
only 5% of participants 
discontinued treatment with 
Divigel 1.0 mg. Further 
research is needed with head 
to head comparison of 
transdermal estradiol 
preparations.  
Dolitsky, S. N., Cordeiro 
Mitchell, C. N., Sheehan 
Stadler, S., & Segars, J. H. 
(2020). Efficacy of progestin-
only treatment for the 




is effective for 
treating VMS 
N=601 SR  
Level 1 
DV=severity and 







Mixed efficacy results 
Largest study using 
transdermal progesterone: 
no improvement (n = 230). 
Monotherapy with 
progestogens can be used to 
treat VMS in women with 

























symptoms: A systematic 


















Side effects (headaches, 
vaginal bleeding, etc.) 
significant in 5 of 7 
studies; treatment 
discontinuation 6%-21%  
Current research with mixed 
results and additional RCTs 
with larger sample sizes are 
needed to determine efficacy, 
safety, and tolerability of 
progesterone only for VMS. 
Eden, J. (2017). The 
endometrial and breast safety 
of menopausal hormone 
therapy containing micronised 
progesterone: A short review. 
Australian & New Zealand 
Journal of Obstetrics & 







breast, and CV 
safety of  
estrogen+MP4 
N/A Narrativ
e review  
 
IV=MP4; various 
forms and doses 
DV=endometrial 









N/A MP4 (oral CC or SC and 
alternate day vaginal) is 
effective in preventing 
endometrial 
hyperplasia/EC 
CV risk: MP4 likely safer 
than P  
 
CEE and oral E2 ↑ risk of 
VTE/stroke but TD E2 (gel 
or patch) does not. MPA 
significantly ↑risk of VTE.  
MP4 “could be safe” 
regarding VTE 
 
BC: HT regimens with 
MP4 have significantly 
↓BC risk compared to P   
 
Oral MP4 200mg cyclic or 
100mg daily and vaginal MP4 
100mg every other day 
adequately protects the 
endometrium when given with 
low to medium dosage 
estrogen to manage 
menopause symptoms.   
 
Transdermal E2 + oral or 
vaginal MP4 is most likely a 
safe and effective option for 
women with moderate to 
severe VMS seeking 
bioidentical HT.  
 
Need large RCTs comparing 
vaginal vs. oral MP4 
 
Need RCTs evaluating MP4 




Gaudard A., Silva de Souza, 
S., Puga, M., Marjoribanks, J., 















low to moderate quality 
evidence that E2 in various 
E2 is likely more effective 
than placebo in treating 
























(2016). Bioidentical hormones 
for women with vasomotor 
symptoms. Cochrane 





















hot flushes and 
night sweats 
Symptom intensity 












or placebo  
forms and doses is more 
effective than placebo  
no evidence showing 
difference in effectiveness 
between bioidentical HT 
and CEE 
Not all studies reported 
analyzable data; no MA 
clear difference in efficacy 
between E2 and CEE.  Dose 
dependent response. 
 
Cannot make specific 
treatment recommendations 
due to study limitations: risk 
of bias/poor reporting of 
methods, imprecision, and 
lack of analyzable data.  
Hodis, H. N., Mack, W. J., 
Henderson, V. W., Shoupe, 
D., Budoff, M. J., Hwang-
Levine, J., Li, Y., Feng, M., 
Dustin, L., Kono, N., 
Stanczyk, F. Z., Selzer, R. H., 
& Azen, S. P. (2016). 
Vascular effects of early 
versus late postmenopausal 
treatment with estradiol. New 






CV effects of 
PM HT (E2) 
vary with timing 
of initiation  
N=643 
healthy PM 









years or late ≥10 
years  
DV=Rate of 
change in CIMT; 
at baseline then 


















Mean CIMT (mm/year) at 
median of 5 years:  
Early menopause group:            
E2 w/ or w/o P4: ↑0.0044    
Placebo ↑0.0078 
Late menopause group:                   
E2 w/ or w/o P4 ↑0.0100   
Placebo 0.0088  
Cardiac CT (all groups; 
mean 6 years follow up): 
coronary artery calcium, 
total stenosis, and plaque 
did not differ significantly  
Oral E2 associated with less 
progression of subclinical 
atherosclerosis (measured by 
CIMT) than placebo if 
initiated within 6 years of 
menopause.  CIMT 
progression was not impacted 
in late menopause group.  
There may be a CV benefit to 
starting estradiol within 6 
years of menopause.   
 
E2 had no significant impact 
on atherosclerosis regardless 
of timing of initiation, 
however no baseline cardiac 
CT was obtained and there 
was a smaller sample size 
receiving post-completion CT.   
Kaunitz, A. M., Bitner, D., 
Constantine, G. D., Bernick, 
B., Graham, S., & Mirkin, S. 
(2020). 17β-






n=726   RCT 
Level 2 
DV=change in 
moderate to severe 
VMS, moderate to 
once-
daily, oral 
E2/P4   
In all treatment groups: Women treated with E2/P4 
had a greater response to 
treatment with more VMS-free 
























single, oral, softgel capsule 
(TX-001HR) significantly 
increased the number of 
vasomotor symptom-free days 
in the REPLENISH 









days at 12 weeks 
VMS diary  
See Lobo 
et al. 2018 
Significant ↑ in 50% and 
75% responders at weeks 4 
& 12  
Significant ↑ in VMS-free 
days at week 12  
43-56% of ♀ without 
severe hot flushes at week 
12 versus 26% for placebo  
Kovács, G., Zelei, T., & 
Vokó, Z. (2016). Comparison 
of efficacy and local 
tolerability of estradiol 
metered-dose transdermal 
spray to estradiol patch in a 
network meta-





efficacy of E2 
MDTS vs. E2 















change (%) in 
number of hot 
flashes between 









All treatment groups 
except 14mcg/day patch 
had a significant ↓ in 
number of hot flashes 
compared to placebo 
No significant difference in 
efficacy between E2 
MDTS and E2 patch; dose 
dependent response  
When applied in similar doses, 
E2 MDTS and E2 patches 
have similar efficacy in 
treating menopausal VMS.  
Lobo R. A., Archer, D. F., 
Kagan, R., Kaunitz, A. M., 
Constantine, G. D., Pickar, J. 
H., Graham, S., Bernick, B., 
& Mirkin, S. A. (2018). 17β-
estradiol-progesterone oral 
capsule for vasomotor 
symptoms in postmenopausal 
women: A randomized 
controlled trial. Obstetrics & 



























moderate to severe 
VMS at weeks 4 











for up to 
52 weeks 
Frequency and severity of 
VMS significantly ↓ from 
baseline with E2/P4 
1mg/100mg and 0.5mg/ 
100mg compared with 
placebo at week 4 and 
week 12  
 
TX-001HR is the first 
continuous combined oral 
E2/P4 capsule to treat 
moderate-to-severe PM VMS 
and provides an effective and 
convenient option for women 
























Lobo, R. A., Kaunitz, A. M., 
Santoro, N., Bernick, B., 
Graham, S., & Mirkin, S. 
(2019). Metabolic and 
cardiovascular effects of TX-
001HR in menopausal women 
with vasomotor symptoms. 











used to treat 
VMS 





factors, and blood 
glucose drawn at 
baseline, 6, 9, and 
12 months 
CV events  
See Lobo 
et al. 2018 
No clinically significant 
effects on lipids, 
coagulation factors, or 
blood glucose between 
treatment groups and 
comparing treatment 
groups with placebo. 
CV adverse events (1 
DVT, 3 CVD) 
Neutral effects on TGs  
 
Lacked statistical power to 
determine CV outcomes 
(stroke, VTE, CHD). 
Incidence of CV events in 
treatment group similar to 
expected rates in general 
population.  
Malik, S., Pannu, D., Prateek, 
S., Sinha, R., & Gaikwad, H. 
(2016). Comparison of the 
symptomatic response in 
Indian menopausal women 
with different estrogen 
preparations for the treatment 
of menopausal symptoms: A 
randomized controlled 
trial. Archives of Gynecology 
































DV= Severity and 
frequency of hot 
flashes  
Hot flash score 
(average hot flash 
severity x daily 
frequency) 
calculated at 
baseline, 4, 12, 24, 
















E2V and CEE ↓severity 
and frequency of hot 
flashes.  
Mean hot flash score at 24-
week follow up: 
E2V: ↓91.9%  
CEE: ↓89.2%  
Isoflavones: ↓60.42%  
Placebo: ↓47.9%  
Low doses of both CEE and 
E2V were equally effective for 
management of VMS when 
administered over 24 weeks.  
 
Mirkin, S., Goldstein, S. R., 
Archer, D. F., Pickar, J. H., 
Graham, S., & Bernick, B. 
(2020). Endometrial safety 
and bleeding profile of a 17β-
estradiol/progesterone oral 
softgel capsule (TX-
001HR). Menopause, 27(4), 
Evaluate 
endometrial 
safety of single 
capsule E2/P4 
(TX-001HR) 
when used to 
treat VMS 





biopsy at baseline 
and 52 weeks 
See Lobo 
et al. 2018 
Incidence of endometrial 
hyperplasia ≤0.36% 
regardless of dose after one 
year of use 
All doses of TX-001HR 
provide adequate endometrial 



























Prior, J. C. (2018). 
Progesterone for treatment of 
symptomatic menopausal 






safety of MP4 
only therapy for 









and intensity of 
hot flashes; VMS 
score calculated 
from daily log 
DV=CV makers  
TD MP4, 
oral MP4, 
w/ or w/o 
ET 
 
RCT (N=133): statistically 
significant ↓VMS score at 
12 weeks (55% decrease 
w/ oral MP4 vs. 29% w/ 
placebo); no serious AEs 
RCT (N=24) no change in 
weight, BP, lipids, waist 
circumference, fasting 
glucose, CRP, or D-dimer 
at 12 weeks compared to 
placebo 
Oral MP4 is likely safe and 
effective in treating 
menopausal VMS either alone 
or in combination with 
estrogen. 
  
Insufficient evidence to 




Santoro, N., Allshouse, A., 
Neal-Perry, G., Pal, L., Lobo, 
R. A., Naftolin, F., Black, D. 
M., Brinton, E. A., Budoff, M. 
J., Cedars, M. I., Dowling, N. 
M., Dunn, M., Gleason, C. E., 
Hodis, H. N., Isaac, B., 
Magnani, M., Manson, J. E., 
Miller, V. M., Taylor, H. S., 
Wharton, W., Wolff, E., 
Zepeda, V., Harman, S. M. 
(2017). Longitudinal changes 
in menopausal symptoms 
comparing women 
randomized to low-dose oral 
conjugated estrogens or 
transdermal estradiol plus 
micronized progesterone 
versus placebo: The Kronos 
Early Estrogen Prevention 
Compare the 
efficacy of low 
dose oral CEE 
vs. TD E2 plus 
MP$ or placebo 
in treating VMS 














DV= reduction in 
moderate-severe 
hot flashes and 
night sweats  
Hot flashes and 
night sweats self-
reported at 
baseline and at 6, 














Moderate to severe hot 
flashes and night sweats: 
Baseline: 44% and 35% 
respectively 
At 6-month follow up:  
Significant ↓ in all 
treatment groups. 
Hot flashes: placebo 
28.3%; TD E2 7.4%; oral 
CEE 4.2%  
Night sweats: placebo 
19%; TD E2 5.3%; oral 
CEE 4.7%  
No significant differences 
between CEE and TD E2  
Lower than conventional 
doses of oral CEE and TD E2 
provide significant relief of 
menopausal VMS up to 48 
months.  Both options are 
equally effective therefore TD 
E2 is a viable option for 
women seeking bioidentical 






























Symptom relief was not 
significantly modified by 
BMI or race/ethnicity. 
Scarabin P. Y. (2018). 
Progestogens and venous 
thromboembolism in 
menopausal women: An 
updated oral versus 
transdermal estrogen meta-














PM ♀ with 
VTE 
MA     
Level 1 




(DVT or PE), 
VTE recurrence, 
or secondary VTE 
Measured with 








or P4 vs. 
non-user 
TD E+MP4: no change 
(RR 0.93, 95% CI 0.65–
1.33) 
TD E+P: ↑VTE risk (RR 
2.42, 95% CI 1.84–3.18) 
Transdermal estrogen+MP4 is 
a safer option for menopausal 
women at risk for VTE. May 
improve risk/benefit ratio of 
HT for all PM women.  
 
Increased VTE risk associated 
with progestogens is not a 
class effect. 
Simon, J. A., Laliberté, F., 
Duh, M. S., Pilon, D., Kahler, 
K. H., Nyirady, J., Davis, P. 
J., & Lefebvre, P. (2016). 
Venous thromboembolism 
and cardiovascular disease 
complications in menopausal 
women using transdermal 
versus oral estrogen therapy. 
Menopause, 23, 600–610. 
https://doi.org/10.1097/GME.
0000000000000590 
Evaluate risk of 
VTE and CVD 
complications 
for menopausal 
♀ using TD 
estradiol vs. oral 
ET 
N=5102  








9 codes on health 
insurance claims 
 







TD E2 vs oral ET  
CVD complications: 
(adjusted IRR 0.81; 95% 
CI, 0.67-0.99). 
VTE (adjusted IRR 0.42; 
95% CI, 0.19-0.96) 
 
Findings suggest that 
unopposed TD E2 is safer 
from a CVD risk standpoint 
when compared to unopposed 
oral estrogens, but no 
conclusions can be drawn 
regarding the safety profiles of 
bioidentical vs. synthetic oral 
ET.   
 
Sjögren, L. L., Mørch, L. S., 
& Løkkegaard, E. (2016). 
Hormone replacement therapy 
and the risk of endometrial 
cancer: A systematic 





safety of PM 
HT use based 












IV= estrogen plus 
CC or SC MP4  
DV= incidence & 
prevalence of EC  
 
N/A Study #1: HR 2.42; 95% 
CI 1.53–3.83 for ever use 
of MP4 vs. never use 
(SC/CC not specified) 
Study #2: HR 1.80; 95% 
CI 1.38–2.34 for ever use 
of CC with MP4 
Increased risk of EC among 
MP4 users.  EC risk higher if 
























HR 1.39; 95% CI 0.99–
1.97 for ≤5 years of CC 
with MP4  
HR 2.66; 95% CI 1.87–
3.77 for >5 years of CC 
with MP4 
Stute, P., Wildt, L., & Neulen, 
J. (2018). The impact of 
micronized progesterone on 
breast cancer risk: A 
systematic 






estrogen + MP4 


















or scheduled visits 
at 2 month or 12- 
month intervals 
Mean duration of 


















No ↑BC risk w/ E+ oral or 
vaginal MP4 use for ≤5 
years 
Limited evidence suggests 
slight but significant ↑BC 
risk w/ E+MP4 >5 years 
Adherence high in two 




Practice recommendations: (1) 
E+MP4 (oral or vaginal) does 
not increase breast cancer risk 
if used for ≤5 years.  Limited 
evidence suggests that BC risk 
increases after 5 years E+ oral 
MP.   
Stute, P., Neulen, J., & Wildt, 
L. (2016). The impact of 
micronized progesterone on 
the endometrium: A 
systematic review. 

















IV=EPT w/ MP4 
(oral, TD, or 
vaginal) for 
minimum of 3 
months 
DV=Endometrial 
hyperplasia & EC 
N/A Oral MP4: adequate 
endometrial protection if 
sequential 200mg/day for 
12-14 day/month for up to 
5 years 
Vaginal MP4: may provide 
endometrial protection if 
sequential for ≥10 days/ 
month at 4% (45 mg/day) 
or every other day at 100 
Detailed expert panel 

























mg/day for up to 3–5 years 
(off-label use) 
TD MP4 does not provide 
endometrial protection 
Tempfer, C. B., Hilal, Z., 
Kern, P., Juhasz-Boess, I., & 
Rezniczek, G. A. (2020). 
Menopausal hormone therapy 
and risk of endometrial 
cancer: A systematic 




risk in ♀ related 











IV= estrogen plus 
CC or SC MP4  
DV= incidence & 
prevalence of EC  
 
N/A Study #1: HR 2.42; 95% 
CI 1.53–3.83 for ever use 
of MP4 vs. never use 
(SC/CC not specified) 
Study #2: HR 1.80; 95% 
CI 1.38–2.34 for ever use 
of CC with MP4 
HR 1.39; 95% CI 0.99–
1.97 for ≤5 years of CC 
with MP4  
HR 2.66; 95% CI 1.87–
3.77 for >5 years of CC 
with MP4 
Increased risk of EC among 
MP4 users.  Short term use 






Yang, Z., Hu, Y., Zhang, J., 
Xu, L., Zeng, R., & Kang, D. 
(2017). Estradiol therapy and 
breast cancer risk in 
perimenopausal and 
postmenopausal women: A 
systematic review and meta-
analysis. Gynecological 























exposure, type of 
regimen (CC/SC) 
DV=BC incidence 




MP4 or P 
 
OR (95% CI): 
E2V/E2 only  
All studies 1.11 (0.98-1.27) 
RCT only 0.90 (0.40-2.02) 
EPT w/ progestogen: 
MP4 1.00 (0.83-1.20) 
MPA 1.19 (1.07-1.33) 
NETA 1.44 (1.26-1.65) 
No increased risk of BC with 
EV and 17-beta estradiol.   
 
Statistically significant ↑in BC 
risk with EPT including 
synthetic P (MPA, NETA, 
LNG).  No ↑BC risk with EPT 
containing MP4. 
 
↑BC risk with EPT <5 years 
(MA included bioidentical 
estradiol but combined all 
























LNG 1.47 (1.17-1.85) 
EPT <5yrs 1.39 (1.09-1.78) 
EPT >5yrs 2.25 (1.82-2.80) 
EPT SC 1.76 (1.28-2.42) 
EPT CC 2.90 (1.82-4.61) 
years increases BC risk even 
further.  
 
Statistically significant ↑ BC 
risk with SC and CC EPT, 
however higher risk with CC. 
Zeng, Z., Jiang, X., Li, X., 
Wells, A., Luo, Y., & 
Neapolitan, R. (2018). 
Conjugated equine estrogen 
and medroxyprogesterone 
acetate are associated with 
decreased risk of breast cancer 
relative to bioidentical 
hormone therapy and 






















DV=BC diagnosis  




Mean follow up 
time 15.4 years 
(HT use) and 17.8 
years (controls) 






BC risk (95% CI): 
CEE (HR 0.31)  
Oral E2 (HR 0.65)  
CEE+MPA (HR 0.43) 
E2+MP4 (HR 1.05)  
CEE and CEE+MPA had the 
lowest risk of BC.  
Oral E2 was associated with 
↓BC risk but inferior to CEE.  
 
CEE+MPA findings differed 
from WHI 
 
Need additional studies to 
substantiate results 
AA, African American; BC, breast cancer; BP, blood pressure; CC, continuous combined; CCS, case control study; CEE, conjugated equine estrogens; CI, confidence interval; CID, clinically important 
differences; CIMT, carotid artery intima-media thickness; CMA, chlormadinone acetate; CRP, C reactive protein; CS, cohort study; CV, cardiovascular; D, dydrogesterone; DBPC, double blind placebo-controlled; 
DV, dependent variable; E, estrogen; E2, estradiol; E2V, estradiol valerate; EPT, estrogen-progesterone therapy; ET, estrogen therapy; EV, estradiol valerate; HR, hazard ratio; HT, hormone therapy; ICD-9, 
International Classification of Diseases, Ninth Revision; IRR, Incidence Rate Ratio; IS, ischemic stroke; IV, independent variable; LNG, levonorgestrel; MA, meta-analysis; MP4, micronized progesterone; MPA, 
medroxyprogesterone acetate; MDTS, meter-dose transdermal spray; NETA, norethisterone acetate; OR, odds ratio; P, synthetic progestin; PBCCS, population based case control study; PM, post-menopause; 
PROLMRDS, partly randomized open-label, multiple-rising-dose study; RCT, randomized control trial; RR, relative risk; SC, sequential combined; SR, systematic review; TG, triglycerides 
 
